CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Surge in adoption of autoimmune disease therapeutics
3.3.1.2. Increase in incidence of autoimmune disease
3.3.1.3. Wide availibility of adavanced therapeutics
3.3.2. Restraints
3.3.2.1. Higher cost assosiated with advanced autoimmune disease therapeutics
3.3.3. Opportunities
3.3.3.1. Growth opportunities in emerging economies
3.3.3.2. Strong presence of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-inflammatory
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Antihyperglycemics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. NSAIDs
4.4.1 Key market trends, growth factors, and opportunities
4.4.2 Market size and forecast
4.4.3 Market analysis, by country
4.5 Interferons
4.5.1 Key market trends, growth factors, and opportunities
4.5.2 Market size and forecast
4.5.3 Market analysis, by country
4.6 Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
CHAPTER 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Rheumatic Disease
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Type 1 Diabetes
5.3.1 Market size and forecast, by region
5.3.2 Market analysis, by country
5.4 Multiple Sclerosis
5.4.1 Market size and forecast, by region
5.4.2 Market analysis, by country
5.5 Inflammatory Bowel Disease
5.5.1 Market size and forecast, by region
5.5.2 Market analysis, by country
5.6 Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacy
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Drug store & retail pharmacy
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Store
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. autoimmune disease therapeutics market, by drug class
6.2.2.1.2. U.S. autoimmune disease therapeutics market, by indication
6.2.2.1.3. U.S. autoimmune disease therapeutics market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Canada autoimmune disease therapeutics market, by indication
6.2.2.2.3. Canada autoimmune disease therapeutics market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Mexico autoimmune disease therapeutics market, by indication
6.2.2.3.3. Mexico autoimmune disease therapeutics market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.5.4. North America market size and forecast, by indication
6.2.5. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Germany autoimmune disease therapeutics market, by indication
6.3.2.1.3. Germany autoimmune disease therapeutics market, by sales channel
6.3.2.2. France
6.3.2.2.1. France autoimmune disease therapeutics market, by drug class
6.2.2.1.2. France autoimmune disease therapeutics market, by indication
6.3.2.2.3. France autoimmune disease therapeutics market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK autoimmune disease therapeutics market, by drug class
6.2.2.1.2. UK. autoimmune disease therapeutics market, by indication
6.3.2.3.3. UK autoimmune disease therapeutics market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Italy autoimmune disease therapeutics market, by indication
6.3.2.4.3. Italy autoimmune disease therapeutics market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Spain autoimmune disease therapeutics market, by indication
6.3.2.5.3. Spain autoimmune disease therapeutics market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of Europe autoimmune disease therapeutics market, by indication
6.3.2.6.3. Rest of Europe autoimmune disease therapeutics market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.5.4. Europe market size and forecast, by indication
6.3.5. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Japan autoimmune disease therapeutics market, by indication
6.4.2.1.3. Japan autoimmune disease therapeutics market, by sales channel
6.4.2.2. China
6.4.2.2.1. China autoimmune disease therapeutics market, by drug class
6.2.2.1.2. China autoimmune disease therapeutics market, by indication
6.4.2.2.3. China autoimmune disease therapeutics market, by sales channel
6.4.2.3. Australia
6.4.2.3.1. Australia autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Australia autoimmune disease therapeutics market, by indication
6.4.2.3.3. Australia autoimmune disease therapeutics market, by sales channel
6.4.2.4. India
6.4.2.4.1. India autoimmune disease therapeutics market, by drug class
6.2.2.1.2. India autoimmune disease therapeutics market, by indication
6.4.2.4.3. India autoimmune disease therapeutics market, by sales channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea autoimmune disease therapeutics market, by drug class
6.2.2.1.2. South Korea autoimmune disease therapeutics market, by indication
6.4.2.5.3. South Korea autoimmune disease therapeutics market, by sales channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of Asia-Pacific autoimmune disease therapeutics market, by indication
6.4.2.6.3. Rest of Asia-Pacific autoimmune disease therapeutics market, by sales channel
6.4.3. Asia-Pacific market size and forecast, by type
6.5.4. Asia-Pacific market size and forecast, by indication
6.4.5. Asia-Pacific market size and forecast, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Brazil autoimmune disease therapeutics market, by indication
6.5.2.1.3. Brazil autoimmune disease therapeutics market, by sales channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Saudi Arabia autoimmune disease therapeutics market, by indication
6.5.2.2.3. Saudi Arabia autoimmune disease therapeutics market, by sales channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa autoimmune disease therapeutics market, by drug class
6.2.2.1.2. South Africa autoimmune disease therapeutics market, by indication
6.5.2.3.3. South Africa autoimmune disease therapeutics market, by sales channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of LAMEA autoimmune disease therapeutics market, by indication
6.5.2.4.3. Rest of LAMEA autoimmune disease therapeutics market, by sales channel
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by indication
6.5.5. LAMEA market size and forecast, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. AbbVie Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Amgen Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. AstraZeneca plc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Bristol-Myers Squibb Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. F. Hoffmann-La Roche AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Novartis AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. UCB S.A.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and development